Perlecan Pharma Private Limited is India's first integrated drug development company and is promoted by Dr. Reddy's Laboratories Limited (DRL) with equity capital commitment from ICICI Venture and other investors. The capital committed is to be used for funding R&D, clinical development and drug filing costs of 4 molecules. Perlecan Pharma has in-licensed 4 NCEs (New Chemical Entities) in the area of Cardiovascular and Metabolic disorders from DRL. The company's key objective is to advance the clinical development of NCE assets through Phase II and thereafter seek out-licensing, co-development or joint commercialization opportunities.